Reports Q3 revenue $592.2M, consensus $514.8M. “Results in the third quarter were excellent, including our largest increase in quarterly clinical MRD units to date,” said Steve Chapman, chief executive officer of Natera (NTRA). “We continue to advance innovation across the portfolio, with successful read-outs for Signatera(TM), positive new results for our early cancer detection program, and the announcement of an expanded panel for our Fetal Focus(TM) single-gene noninvasive prenatal test.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera announces data from PROCEED-CRC trial
- Natera Inc.’s New Prenatal Test Study: A Potential Game-Changer in Genetic Screening
- Natera’s New Study: A Potential Game-Changer in Breast Cancer Treatment
- Natera’s FIND-CRC Study: A Potential Game-Changer in Colorectal Cancer Screening
- Natera Inc.’s Innovative Approach to Heart Transplant Rejection Monitoring: A Study Update